Navigation Links
Addrenex Pharmaceuticals Reaches Milestone with Filing of NDA for First Product, CloniBID, to Treat Hypertension
Date:2/20/2008

RESEARCH TRIANGLE PARK, N.C., Feb. 20 /PRNewswire/ -- Addrenex Pharmaceuticals has reached its first milestone accomplishment this year with the filing of a new drug application (NDA) for its first drug, CloniBID, to treat hypertension. Upon approval from the Food and Drug Administration, Addrenex and its licensing partner Sciele Pharma, Inc. will launch the drug in the first half of 2009.

Addrenex has moved swiftly to develop and commercialize CloniBID, a sustained-release formulation of clonidine hydrochloride. The company recently entered its second year of operation and already has developed and tested its two lead products, CloniBID for hypertension and Clonicel for the treatment of attention deficit hyperactivity disorder (ADHD). Clonicel is currently undergoing phase 3 clinical trials nationwide and will complete the trials by the end of the year.

Both drugs are designed to circumvent the bothersome side effects of generic clonidine, including a peak of sedation when the drug is absorbed and a subsequent rebound of hypertension once the drug's effects wear off. Such unwanted "peaks and troughs" have limited the drug's use in some patients who otherwise have responded very well to the drug's beneficial effects, said Moise Khayrallah, cofounder and CEO of Addrenex.

Last year, Addrenex quickly acquired the necessary data to attract Sciele's interest in licensing the rights to market both drugs. Sciele purchased a $6 million equity stake in Addrenex, with the potential for an additional $11 million in milestone payments. Sciele also holds the first right of refusal to market Addrenex's future products in the areas of pediatrics, women's health, cardiovascular and metabolic diseases.

The agreement with Sciele in June was followed by a second contract in December, granting Addrenex the rights to a vast library of nearly 400 compounds at the University of Nebraska Medical Center. The library of compounds focuses on adrenergic regul
'/>"/>

SOURCE Addrenex Pharmaceuticals
Copyright©2008 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2

Related biology technology :

1. Vion Pharmaceuticals to Implement a One-for-Ten Reverse Stock Split
2. Sunesis Pharmaceuticals Announces Milestone Payment from Inflammation Collaboration
3. Arena Pharmaceuticals to Report Fourth Quarter and Full Year 2007 Financial Results and to Host Conference Call and Webcast on Wednesday, February 27, 2008
4. Watson Pharmaceuticals Reports Fourth Quarter and Full Year 2007 Results; Provides 2008 Outlook
5. Graceway Pharmaceuticals, LLC(TM) Announces Completed Acquisition of All Assets Related to Estrasorb(R) Product Line in North America From Allergan, Inc. (NYSE: AGN) and Novavax, Inc. (Nasdaq: NVAX)
6. Novavax Enters Into Estrasorb(R) Asset Sale and Supply Agreements with Graceway Pharmaceuticals, LLC
7. Boehringer Ingelheim Pharmaceuticals, Inc. Receives the NCQA Seal Of Approval
8. Onyx Pharmaceuticals Announces a Teleconference and Webcast to Provide an Update on Nexavar and Report Full Year 2007 Financial Results
9. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
10. Keryx Biopharmaceuticals Announces Additions to Management Team
11. Cadence Pharmaceuticals to Raise up to $49.3 Million in Registered Direct Common Stock Offering

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/5/2009)... The endangered black-footed ferret...his rare carnivore feeds on prairie dogs. The pr...n entire population die-offs in towns occur. The ...nted a ferret breeding program and has been releas...ative habitat. Unfortunately, plague can sweep th...
(Date:11/5/2009)...ire-FirstCall/ -- Imagenetix, Inc. (OTC Bulletin B... President and CEO of Imagenetix, will be presenti...Conference on Thursday, December 3rd, at 10:30 AM ... LD MICRO ,, LD MICRO is a by-invitation only n... companies in the micro-cap space. Since 2002, the...
(Date:11/5/2009)...y, November 5, 2009 at 4:30 p.m. Eastern Time ,...rstCall/ - OncoGenex Pharmaceuticals, Inc. ("OncoG...orted unaudited financial results for the third qu... reviewed the Company,s highlights for the third q...esults reflect the operations of OncoGenex Technol...
(Date:11/5/2009)...Newswire-FirstCall/ -- BioSpecifics Technologies C... developing first-in-class collagenase-based produ... third quarter ended September 30, 2009. ,, "W...year, the FDA,s Arthritis Advisory Committee unani...l of XIAFLEX(TM) for the treatment of Dupuytren,s ...
Breaking Biology Technology:Colorado Companies Team Up With U.S. Fish & Wildlife Service to Protect Black-Footed Ferret 2Imagenetix to Present at 2nd Annual LD MICRO Conference at the Luxe Sunset Bel Air 2OncoGenex Reports Third Quarter 2009 Financial Results 2OncoGenex Reports Third Quarter 2009 Financial Results 3OncoGenex Reports Third Quarter 2009 Financial Results 4OncoGenex Reports Third Quarter 2009 Financial Results 5OncoGenex Reports Third Quarter 2009 Financial Results 6OncoGenex Reports Third Quarter 2009 Financial Results 7OncoGenex Reports Third Quarter 2009 Financial Results 8BioSpecifics Technologies Corp. Reports Third Quarter 2009 Financial Results 2BioSpecifics Technologies Corp. Reports Third Quarter 2009 Financial Results 3BioSpecifics Technologies Corp. Reports Third Quarter 2009 Financial Results 4BioSpecifics Technologies Corp. Reports Third Quarter 2009 Financial Results 5
... Codexis, Inc. today announced,a licensing agreeme...oduce an,important publicly-undisclosed generic pr...eva, the largest generic drug manufacturer in the ...ct. The product is one of the largest-,selling ge... Under the agreement, Teva would be using the Co...
...tradigm Corporation, a leading,developer of target... today,announced that the company has closed the f...enture Management led the $2.9 million tranche, wi...pating. The addition of these,funds brings the to...m will,use Series B funds to advance its RNAi ther...
...s, Inc. (Nasdaq: ABAX ), a medical products comp...truments for both the medical and veterinary marke...ense agreement for co-exclusive worldwide rights i...ofessional marketplace for certain technologies pe...ethods. , , This license agreement provides Abaxi...
Other Biology Technology:Codexis, Teva in Licensing Agreement Final 2Intradigm Closes Final Tranche of $21.4 Million Series B Financing 2Intradigm Closes Final Tranche of $21.4 Million Series B Financing 3ABAXIS Announces Worldwide Animal Health Licensing Agreement for Rapid Test Technology 2ABAXIS Announces Worldwide Animal Health Licensing Agreement for Rapid Test Technology 3
(Date:11/4/2009)...ence) , United States Using Less Water Today ...t did 35 years ago, despite a 30 percent populatio...butable to alternative cooling methods at power pl...ing to the latest USGS water use report, nearly ha...cooling thermoelectric power plants. Irrigation ac...
(Date:11/4/2009)...an has received more than $10 million in research ...ederal stimulus program, bringing thetotal amount ...$23 million. Thirty-three projects achieved stimu...o weather. , "The university has thoughtfully un... scholarly excellence to federal agency priorities...
(Date:11/4/2009)...re/ -- What,s the cost of saving a teenage life? W...ing from prescription medication abuse, there,s no... may be unaware that the lock-boxes they,ve instal...g timebomb of prescription drugs. That,s why MEDNE...l supplies, has formed an exclusive partnership wi...
Breaking Biology News(10 mins):USGS science picks 2USGS science picks 3USGS science picks 4USGS science picks 5USGS science picks 6USGS science picks 7OU achieves $10 million in stimulus grants for 33 projects on the Norman campus 2OU achieves $10 million in stimulus grants for 33 projects on the Norman campus 3MEDNET Launches MedSafe to Prevent Teenage Prescription Drug Abuse 2MEDNET Launches MedSafe to Prevent Teenage Prescription Drug Abuse 3Country United symposium explores collaborative future of military medicine 58428 1Country United symposium explores collaborative future of military medicine 58428 2Country United symposium explores collaborative future of military medicine 58428 3Critical Zone Observatory seeks to answer climate change questions 10146 1Critical Zone Observatory seeks to answer climate change questions 10146 2Critical Zone Observatory seeks to answer climate change questions 10146 3Critical Zone Observatory seeks to answer climate change questions 10146 4Dr Richard Feinman to speak on the science of diabetes and diet on Oct 2 10142 1
...l known that the bodys energy levels cycle on a 24...olic process is fueled by oxygen. Now, researchers...ine have found that a protein called Rev-erb coord...lecules to maintain the bodys correct metabolism. ...ce Express in advance of print publication in Scie...
...ers at Cincinnati Childrens have issued the first ...blood clotting (fibrin), also plays an important r...f rheumatoid arthritis. Inflammatory joint disease...atory cells with fibrin matrices through a specifi... issue of The Journal of Clinical Investigation, r...
... heck of a commute., The record holder in the Pac...as tagged in the Clearwater River, Idaho, in April...the southern Kuril Islands near Japan. The most di...lies, as they say is 4,200 miles. Imagine fish th...ck to their home streams in order to spawn., The ...
Other Biology News:A mechanism to explain biological 'cross-talk' between 24-hour body cycle and metabolism 2Blood clotting protein linked to rheumatoid arthritis 2UW launches cutting-edge DNA 'fin-printing' project for salmon 2UW launches cutting-edge DNA 'fin-printing' project for salmon 3
...)-HODE-d4 contains 4 deuterium atoms at the 9, 10,...n internal standard for the quantification of 13(S...is produced by incubation of linoleic acid with pl... to inhibit the adhesion of tumor cells to the end...
Adaptor BamH I-Sma I from Takara Mirus Bio
Adaptor Sal I - Sma I from Takara Mirus Bio
Cassette, Sal I from Takara Mirus Bio
Biology Products: